Pretargeting kit for imaging or therapy comprising a trans-cyclooctene dienophile and a diene
Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.
1. A kit for targeted medical imaging and/or therapeutics, comprising at least one pre-targeting probe and at least one effector probe, wherein the pre-targeting probe comprises a primary targeting moiety and a first bio-orthogonal reactive group, and wherein the effector probe comprises an effector moiety, such as a label or a pharmaceutically active compound, and a second bio-orthogonal reactive group, wherein either of the first and second bio-orthogonal reactive groups is a dienophile and the other of the first and second bio-orthogonal reactive groups is a diene, wherein the dienophile is a trans-cyclooctene moiety comprising at least two exocyclic bonds fixed in the same plane, and comprising at least one linkage, either directly or by way of a spacer, to the pre-targeting probe or the effector probe, wherein the dienophile is a compound selected from the following structures, said structures showing N-hydroxy succinimide ester groups:
said compound further comprising the at least one linkage which links the dienophile, either directly or by way of a spacer, to the pre-targeting probe or the effector probe, said linkage being in the position of said N-hydroxy succinimide ester groups.
2. A compound comprised in a kit for targeted medical imaging and/or therapeutics, comprising at least one pre-targeting probe and at least one effector probe, wherein the pre-targeting probe comprises a primary targeting moiety and a first bio-orthogonal reactive group, and wherein the effector probe comprises an effector moiety, such as a label or a pharmaceutically active compound, and a second bio-orthogonal reactive group, wherein either of the first and second bio-orthogonal reactive groups is a dienophile and the other of the first and second bio-orthogonal reactive groups is a diene, wherein the dienophile is a trans-cyclooctene moiety comprising at least two exocyclic bonds fixed in the same plane, and comprising at least one linkage, either directly or by way of a spacer, to the pre-targeting probe or the effector probe, the compound being selected from the following structures, said structures showing N-hydroxy succinimide ester groups:
said compound further comprising the at least one linkage which links the dienophile, either directly or by way of a spacer, to the pre-targeting probe or the effector probe, said linkage being in the position of said N-hydroxy succinimide ester groups.
3. A kit for targeted medical imaging and/or therapeutics, comprising at least one pre-targeting probe and at least one effector probe, wherein the pre-targeting probe comprises a primary targeting moiety and a first bio-orthogonal reactive group, and wherein the effector probe comprises an effector moiety, such as a label or a pharmaceutically active compound, and a second bio-orthogonal reactive group, wherein either of the first and second bio-orthogonal reactive groups is a dienophile and the other of the first and second bio-orthogonal reactive groups is a diene, wherein the dienophile is a trans-cyclooctene moiety comprising at least two exocyclic bonds fixed in the same plane, and comprising at least one linkage which links the dienophile, either directly or by way of a spacer, to the pre-targeting probe or the effector probe, or comprising at least one linkage which links the diene, either directly or by way of a spacer, to the pre-targeting probe or the effector probe; and
wherein the at least two exocyclic bonds are part of a substantially flat fused ring structure.
4. A kit for targeted medical imaging and/or therapeutics, comprising at least one pre-targeting probe and at least one effector probe, wherein the pre-targeting probe comprises a primary targeting moiety and a first bio-orthogonal reactive group, and wherein the effector probe comprises an effector moiety, such as a label or a pharmaceutically active compound, and a second bio-orthogonal reactive group, wherein either of the first and second bio-orthogonal reactive groups is a dienophile and the other of the first and second bio-orthogonal reactive groups is a diene, wherein the dienophile is a trans-cyclooctene moiety comprising at least two exocyclic bonds fixed in the same plane, and comprising at least one linkage which links the dienophile, either directly or by way of a spacer, to the pre-targeting probe or the effector probe, or comprising at least one linkage which links the diene, either directly or by way of a spacer, to the pre-targeting probe or the effector probe; and
wherein the at least two exocyclic bonds are part of a substantially flat fused ring structure and at least two exocyclic bonds are part of a fused aromatic ring.